Longboard Pharmaceuticals (LBPH) Competitors $59.98 +0.02 (+0.03%) (As of 12/2/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends LBPH vs. ITCI, ROIV, ASND, RVMD, LNTH, LEGN, NUVL, ELAN, CYTK, and BPMCShould you be buying Longboard Pharmaceuticals stock or one of its competitors? The main competitors of Longboard Pharmaceuticals include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Revolution Medicines (RVMD), Lantheus (LNTH), Legend Biotech (LEGN), Nuvalent (NUVL), Elanco Animal Health (ELAN), Cytokinetics (CYTK), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Longboard Pharmaceuticals vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Revolution Medicines Lantheus Legend Biotech Nuvalent Elanco Animal Health Cytokinetics Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Longboard Pharmaceuticals (NASDAQ:LBPH) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, community ranking, risk, profitability, media sentiment, valuation and dividends. Is ITCI or LBPH more profitable? Longboard Pharmaceuticals has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Longboard Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Longboard Pharmaceuticals N/A -33.03%-30.90% Which has more risk & volatility, ITCI or LBPH? Intra-Cellular Therapies has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500. Comparatively, Longboard Pharmaceuticals has a beta of 1, meaning that its stock price has a similar volatility profile to the S&P 500. Do insiders and institutionals hold more shares of ITCI or LBPH? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. Comparatively, 63.3% of Longboard Pharmaceuticals shares are owned by institutional investors. 2.6% of Intra-Cellular Therapies shares are owned by insiders. Comparatively, 4.6% of Longboard Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate ITCI or LBPH? Intra-Cellular Therapies presently has a consensus price target of $97.23, suggesting a potential upside of 15.75%. Longboard Pharmaceuticals has a consensus price target of $59.56, suggesting a potential downside of 0.71%. Given Intra-Cellular Therapies' stronger consensus rating and higher probable upside, research analysts plainly believe Intra-Cellular Therapies is more favorable than Longboard Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Longboard Pharmaceuticals 0 Sell rating(s) 5 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.44 Which has higher valuation and earnings, ITCI or LBPH? Longboard Pharmaceuticals has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Longboard Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$612.78M14.53-$139.67M-$0.87-96.55Longboard PharmaceuticalsN/AN/A-$54.42M-$2.23-26.90 Does the MarketBeat Community prefer ITCI or LBPH? Intra-Cellular Therapies received 458 more outperform votes than Longboard Pharmaceuticals when rated by MarketBeat users. However, 75.00% of users gave Longboard Pharmaceuticals an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Longboard PharmaceuticalsOutperform Votes6375.00% Underperform Votes2125.00% Does the media prefer ITCI or LBPH? In the previous week, Intra-Cellular Therapies had 1 more articles in the media than Longboard Pharmaceuticals. MarketBeat recorded 4 mentions for Intra-Cellular Therapies and 3 mentions for Longboard Pharmaceuticals. Intra-Cellular Therapies' average media sentiment score of 1.06 beat Longboard Pharmaceuticals' score of 0.00 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Longboard Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIntra-Cellular Therapies beats Longboard Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Ad Prosper Trading AcademyA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading system finds high-probability option trades in less than 60 seconds a dayClick HERE to access this powerful AI Trading System Get Longboard Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LBPH vs. The Competition Export to ExcelMetricLongboard PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.34B$6.69B$5.20B$9.15BDividend YieldN/A3.00%5.12%4.30%P/E Ratio-26.9010.5287.1917.11Price / SalesN/A193.661,163.55122.70Price / CashN/A57.1643.2337.84Price / Book35.925.134.804.78Net Income-$54.42M$151.58M$120.46M$225.43M7 Day PerformanceN/A-1.40%-0.89%-0.78%1 Month Performance0.30%-3.69%14.87%1.05%1 Year Performance899.67%9.07%29.57%15.79% Longboard Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LBPHLongboard Pharmaceuticals0.692 of 5 stars$59.98+0.0%$59.56-0.7%+899.7%$2.34BN/A-26.9020Positive NewsITCIIntra-Cellular Therapies4.0747 of 5 stars$83.94+0.6%$97.23+15.8%+19.4%$8.90B$612.78M-96.48560Positive NewsROIVRoivant Sciences2.8812 of 5 stars$11.95+3.3%$17.93+50.0%+9.9%$8.70B$124.79M2.12860ASNDAscendis Pharma A/S3.0021 of 5 stars$139.42+2.2%$191.77+37.5%+12.2%$8.46B$327.43M-17.25640RVMDRevolution Medicines4.4655 of 5 stars$43.92-0.3%$65.82+49.9%+61.0%$7.39B$742,000.00-12.23443LNTHLantheus4.3124 of 5 stars$90.97+1.9%$131.86+44.9%+52.7%$6.32B$1.50B15.14834LEGNLegend Biotech1.5843 of 5 stars$33.59-1.4%$81.54+142.7%-43.3%$6.13B$520.18M-35.361,800NUVLNuvalent2.2218 of 5 stars$84.05-0.2%$112.60+34.0%+14.7%$5.97BN/A-24.2240Positive NewsELANElanco Animal Health3.7991 of 5 stars$11.77+1.2%$16.71+42.0%-19.2%$5.82B$4.45B29.439,300CYTKCytokinetics3.9516 of 5 stars$49.30+0.9%$84.07+70.5%+9.8%$5.82B$3.22M-9.16250BPMCBlueprint Medicines2.5812 of 5 stars$89.62-0.6%$123.33+37.6%+1.7%$5.69B$434.42M-42.47640 Related Companies and Tools Related Companies ITCI Competitors ROIV Competitors ASND Competitors RVMD Competitors LNTH Competitors LEGN Competitors NUVL Competitors ELAN Competitors CYTK Competitors BPMC Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:LBPH) was last updated on 12/24/2024 by MarketBeat.com Staff From Our Partners"This looks and feels like 2000," says investing legendOur senior analyst Dan Ferris says a new surprise crisis could begin at any moment... and this time, he says i...Stansberry Research | SponsoredA.I. Trading System Helps Some Traders Pocket $1,100 per DAY!What if I told you 60 seconds a day could completely change your life? This AI-powered trading syst...Prosper Trading Academy | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredWe recommended Palantir in 2021, now we’re recommending this...My research indicates there is only one investment that can meet AI's unprecedented demand for energy.Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTiny Mineral, Massive Market OpportunityImagine a mineral so small it fits in the palm of your hand... yet its potential could transform the world's f...i2i Marketing Group, LLC | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longboard Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longboard Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LBPH Stock Alerts